Incretin Atlas › Trials › ELIXA
ELIXA
Lixisenatide · T2D after ACS
Design
- Molecule(s)
- Lixisenatide
- Population
- T2D after ACS
- Official title
- Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
- Sponsor
- Sanofi
- Phase
- Phase 3
- Registry status
- completed · 2010-06 → 2015-02
- Participants
- 6068
- Registry
- NCT01147250
Cardiovascular and kidney outcomes
ELIXA lixisenatide 20 µg vs placebo · T2D after ACS · n = 6068 · 2015 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 4-point MACE primary CV death, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina (first occurrence) | 1.02 | 0.89–1.17 | 406 vs 399 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.98 | 0.78–1.22 | 156 vs 158 | verified |
| All-cause death Death from any cause | 0.94 | 0.78–1.13 | 211 vs 223 | verified |
| Myocardial infarction Fatal or nonfatal myocardial infarction | 1.03 | 0.87–1.22 | 270 vs 261 | verified |
| Stroke Fatal or nonfatal stroke | 1.12 | 0.79–1.58 | 67 vs 60 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure | 0.96 | 0.75–1.23 | 122 vs 127 | verified |
| Expanded MACE (MACE + HF hosp. + revasc. + UA) Primary end point (CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina), hospitalization for heart failure, or coronary revascularization | 1.00 | 0.90–1.11 | 661 vs 659 | verified |
| Expanded MACE (MACE + HF hosp. + UA) Primary end point (CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina) or hospitalization for heart failure | 0.97 | 0.85–1.10 | 456 vs 469 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina (component of the 4-point primary end point; all events, not first-event contribution) | 1.11 | 0.47–2.62 | 11 vs 10 | verified |
Verbatim quotes (9)
- 4-point MACE · Abstract, Results; Table 2
A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17)
- Cardiovascular death · Results, Cardiovascular End Points; Table 2
A total of 156 patients in the lixisenatide group and 158 in the placebo group died from cardiovascular causes (hazard ratio, 0.98; 95% CI, 0.78 to 1.22)
- All-cause death · Results, Cardiovascular End Points; Table 2
Death from any cause was reported in 211 patients (7.0%) in the lixisenatide group and in 223 (7.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.78 to 1.13)
- Myocardial infarction · Results, Cardiovascular End Points; Table 2
270 patients in the lixisenatide group and 261 in the placebo group had a fatal or nonfatal myocardial infarction (hazard ratio, 1.03; 95% CI, 0.87 to 1.22)
- Stroke · Results, Cardiovascular End Points; Table 2
67 patients in the lixisenatide group and 60 in the placebo group had a fatal or nonfatal stroke (hazard ratio, 1.12; 95% CI, 0.79 to 1.58)
- Hospitalisation for heart failure · Results, Cardiovascular End Points; Table 2
hospitalization for heart failure occurred in 122 patients (4.0%) in the lixisenatide group and in 127 (4.2%) in the placebo group (hazard ratio, 0.96; 95% CI, 0.75 to 1.23)
- Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 2 (secondary end points)
Primary end-point event, hospitalization for heart failure, or revascularization 659 (21.7) 11.2 661 (21.8) 11.1 1.00 (0.90–1.11)
- Expanded MACE (MACE + HF hosp. + UA) · Results, Cardiovascular End Points paragraph; Table 2 (secondary end points)
in this expanded end point (hazard ratio, 0.97; 95% CI, 0.85 to 1.10)
- Hospitalisation for unstable angina · Results, Cardiovascular End Points paragraph; Table 2
hospi- talized for unstable angina (hazard ratio, 1.11; 95% CI, 0.47 to 2.62)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: ELIXA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/elixa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.